![]() ![]() Research Funding: Millennium (Inst), Seattle Genetics (Inst), Genentech/Roche (Inst), Pharmacyclics (Inst), Janssen (Inst), Merck (Inst), Kura Oncology (Inst), Forty Seven (Inst), Cyteir (Inst)Ĭonsulting or Advisory Role: Pharmacyclics, Karyopharm Therapeutics Research Funding: Juno Therapeutics (Inst), Kite, a Gilead company (Inst), Acerta Pharma (Inst), TG Therapeutics (Inst), BeiGene (Inst), Pharmacyclics (Inst), Celgene (Inst), Oncternal Therapeutics (Inst), Bristol-Myers Squibb/Sanofi (Inst)Ĭonsulting or Advisory Role: Genentech/Roche, Seattle Genetics, Takeda, Portola Pharmaceuticals, Celgene, Sanofi, Kura Oncology, Merck, Karyopharm Therapeutics, ADC Therapeutics, Daiichi Sankyo, Bristol Myers Squibb/Celgene, Epizyme, Incyte Speakers' Bureau: Pharmacyclics/Janssen, AstraZeneca, BeiGene, Bristol Myers Squibb/Celgene Research Funding: Genentech, Janssen, Celgene, TG TherapeuticsĬonsulting or Advisory Role: Juno Therapeutics, AstraZeneca, BeiGene, Celgene, Pharmacyclics, Bristol Myers Squibb/Celgene Honoraria: AstraZeneca, AbbVie, Pharmacyclics/Janssen, BeiGeneĬonsulting or Advisory Role: AbbVie/Genentech, Pharmacyclics, Ascentage Pharma, BeiGene, Janssen Oncology, Epizyme, AstraZeneca, TG Therapeutics, ADC Therapeutics Research Funding: Pharmacyclics (Inst), AbbVie (Inst), Janssen (Inst), BeiGene (Inst), TG Therapeutics (Inst) Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ( Open Payments).Ĭonsulting or Advisory Role: Janssen, Roche/Genentech, Beigene, AbbVie/Pharmacyclics For more information about ASCO's conflict of interest policy, please refer to or /jco/authors/author-center. Relationships may not relate to the subject matter of this manuscript. I = Immediate Family Member, Inst = My Institution. Relationships are self-held unless noted. All relationships are considered compensated unless otherwise noted. The following represents disclosure information provided by authors of this manuscript. Venetoclax in Previously Treated Waldenström Macroglobulinemia Treonįinal approval of manuscript: All authorsĪccountable for all aspects of the work: All authors Allan, Tanya Siddiqi, Kirsten Meid, Shayna Sarosiek, Andrew R. Treonĭata analysis and interpretation: Jorge J. Guerrera, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Lian Xu, Guang Yang, Christopher J. Advani, Kirsten Meid, Carly Leventoff, Timothy P. FurmanĬollection and assembly of data: Jorge J. ![]() Provision of study materials or patients: John N. PattersonĪdministrative support: Kirsten Meid, Carly Leventoff, Timothy P. Given the manageable safety profile, future studies evaluating venetoclax in combination with anti-CD20 monoclonal antibodies or BTKis are warranted.Ĭonception and design: Jorge J. The findings of our study establish venetoclax as an active and tolerable therapy in patients with previously treated WM, regardless of previous exposure to BTKis. There were no episodes of immunoglobulin M flare, neuropathy, secondary myeloid neoplasms, or arrhythmia associated with venetoclax therapy. Venetoclax was well tolerated with only one episode of laboratory (not clinical) tumor lysis syndrome and manageable neutropenia. Venetoclax monotherapy, up to a dose of 800 mg by mouth once daily for 2 years, induced a high response rate in patients with WM, including 50% of patients previously exposed to Bruton tyrosine kinase inhibitors (BTKis) and 38% refractory to the preceding line of therapy. 6 or newer Intel-based.Is venetoclax monotherapy a safe and effective therapy in patients with previously treated Waldenström macroglobulinemia (WM)?
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |